AstraZeneca (AZN) Stock Forecast & Price Target

£121.80

+120.00 (+1.00%)

(As of 07/26/2024 ET)

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a sell rating, 2 have given a hold rating, and 6 have given a buy rating for AZN.

Consensus Price Target

£105.53

High Forecast	£150
Average Forecast	£105.53
Low Forecast	GBX 74

According to the 9 analysts' twelve-month price targets for AstraZeneca, the average price target is £105.53. The highest price target for AZN is £150, while the lowest price target for AZN is GBX 74. The average price target represents a forecasted downside of -13.35% from the current price of £121.80.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	£105.53	£121.57	£116.86	£119.86

Get AstraZeneca Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Ad DTI

We’re in a code red crisis and 99% of Americans are clueless

Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES!

And how YOU can prepare for the next 2024 BOOM here!

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies
Consensus Rating Score	2.56	2.72
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/25/2024	Shore Capital 1 of 5 stars		Reiterated Rating	Buy
7/2/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Hold	GBX 71 ➝ GBX 74	-99.39%
6/18/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Reiterated Rating	Hold	£110	-11.50%
6/7/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	£130 ➝ £150	+19.13%
6/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
5/28/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
Get the Latest News and Ratings for AZN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.
4/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	£125	+18.56%
2/12/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/12/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell	£107 ➝ GBX 9,900	+4.16%
9/25/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		£127 ➝ £129	+15.72%
4/11/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		£127 ➝ £119	+2.20%
2/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dominic Lunn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		£118	+3.60%
2/9/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keyur Parekh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		GBX 6,950	-37.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:48 PM ET.

AZN Forecast - Frequently Asked Questions

What is AstraZeneca's forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £105.53, with a high forecast of £150 and a low forecast of GBX 74.
Should I buy or sell AstraZeneca stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares.
Does AstraZeneca's stock price have much downside?: According to analysts, AstraZeneca's stock has a predicted downside of -6.65% based on their 12-month stock forecasts.
What analysts cover AstraZeneca?: AstraZeneca has been rated by research analysts at Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., and Shore Capital in the past 90 days.
Do Wall Street analysts like AstraZeneca more than its competitors?: Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.56 while the average consensus rating score for "medical" companies is 2.72. Learn more on how AZN compares to other companies.